Provided by Tiger Fintech (Singapore) Pte. Ltd.

Qiagen NV

49.32
-0.0300-0.06%
Post-market: 49.320.00000.00%17:23 EDT
Volume:673.82K
Turnover:33.20M
Market Cap:10.69B
PE:29.13
High:49.53
Open:49.50
Low:49.06
Close:49.35
52wk High:51.88
52wk Low:37.63
Shares:216.83M
Float Shares:214.77M
Volume Ratio:0.90
T/O Rate:0.31%
Dividend:0.25
Dividend Rate:0.51%
EPS(TTM):1.69
EPS(LYR):0.3862
ROE:10.81%
ROA:9.00%
PB:3.05
PE(LYR):127.70

Loading ...

Qiagen NV to Release Third Quarter 2025 Results

Reuters
·
Oct 13

Qiagen Is Maintained at Overweight by Barclays

Dow Jones
·
Oct 02

Sysmex and QIAGEN Sign Exclusive Distribution Agreement for Infectious Disease and Oncology Diagnostics in Japan

Reuters
·
Oct 01

Bank of America Securities Keeps Their Buy Rating on Qiagen (QGEN)

TIPRANKS
·
Sep 26

Berenberg Bank Remains a Buy on Qiagen (QGEN)

TIPRANKS
·
Sep 24

Qiagen NV to Release Half-Year 2025 Financial Results

Reuters
·
Sep 23

Qiagen (NYSE:QGEN) Valuation in Focus Following FDA Clearance and Expansion Plans in U.S. Diagnostics

Simply Wall St.
·
Sep 22

Qiagen (QGEN) Gets a Hold from Kepler Capital

TIPRANKS
·
Sep 12

Qiagen NV Secures CE-IVDR Certification for Full QIAstat-Dx Portfolio, Setting New Standard in CNS Infection Diagnostics

Reuters
·
Sep 11

QIAGEN N.V. Announces $750 Million Non-US Offering of Convertible Bonds

Reuters
·
Sep 02

Qiagen Says US FDA Clears Syndromic Testing System

MT Newswires Live
·
Sep 02

Qiagen Gains U.S. Clearance Of Higher-Throughput Qiastat-Dx Rise

Reuters
·
Sep 02

QIAGEN Gains FDA Clearance for High-Throughput QIAstat-Dx Rise, Enhancing Syndromic Testing in the U.S

Reuters
·
Sep 02

Qiagen NV Announces $750 Million Non-US Offering of Net Share Settled Convertible Bonds

Reuters
·
Aug 28

Qiagen NV Releases Transcript for Second Quarter 2025 Results Call

Reuters
·
Aug 22

Qiagen NV Reports 7% Increase in Q2 2025 Net Sales to $533.5M, Driven by Strong Consumables Demand

Reuters
·
Aug 22

Qiagen NV Announces Manager's Sale of Shares Worth $910,286 on NYSE

Reuters
·
Aug 19

Qiagen N.V. Executive Roland Sackers Sells Shares Worth $2.46 Million on NYSE

Reuters
·
Aug 18

UBS Adjusts Price Target on QIAGEN to $50 From $48, Maintains Neutral Rating

MT Newswires Live
·
Aug 07

Qiagen Nv : JP Morgan Raises Target Price to $60.00 From $50.00

THOMSON REUTERS
·
Aug 07